Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
Tempus AI (NASDAQ:TEM) reported second-quarter revenue growth of 22% and raised its full-year outlook, citing accelerating oncology testing volumes, expanding demand for its data and artificial intelligence offerings, and expected reimbursement benefits from newly approved diagnostic products. Reve
Tempus AI (TEM) spent three years selling someone else's cancer test. On Monday, July 20, it decided to just buy the whole thing. The AI diagnostics company agreed to acquire Personalis (PSNL) in a deal valued at $1.5 billion. The move hands Tempus full control of a test that spots cancer ...
The deal, structured as an all-stock transaction, gives Tempus control of Personalis' NeXT Personal cancer detection test
Under the deal, Personalis’ minimal residual disease (MRD) test will be integrated into Tempus’ broader oncology portfolio.
Tempus AI (NASDAQ:TEM) executives said the company’s planned acquisition of Personalis is intended to strengthen its position in minimal residual disease, or MRD, testing, while expanding its biopharma data and profiling capabilities. On a call with analysts, Tempus said it agreed to acquire all ou
By Karen Roman CareDx, Inc. (Nasdaq: CDNA) said it completed the acquisition of Naveris, which includes its leading product, NavDx, a blood-based test for viral-mediated cancer detection including human papillomavirus, and associated head and neck and anal cancers. NavDx is the first and only Medicare-covered test for HPV-driven head and neck and anal cancer molecular […] The post CareDx Acquires Naveris, Extends Leadership into High-Growth Specialty Oncology appeared first on ExecEdge.
Tempus (TEM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Tempus AI (NASDAQ:TEM) reported first-quarter 2026 revenue of $348.1 million, up a little over 36% year over year, as the company posted growth across both its diagnostics and data and applications segments and raised its full-year outlook. Founder and CEO Eric Lefkofsky said diagnostics revenue ca
Moby summary of Tempus AI, Inc.'s Q1 2026 earnings call
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
